A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
The global enrollment phase has closed, but participants are still being recruited only at sites in China.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 658 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)
Actual Study Start Date: March 11, 2019
Actual Primary Completion Date: October 5, 2020
Estimated Study Completion Date: November 30, 2022
Arm:
- Experimental: Faricimab
- Active Comparator: Aflibercept
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Actual enrolment | 658 |
| Actual Study start date | 11 March 2019 |
| Estimated Study Completion Date | 30 November 2022 |